CliffBio
small molecule

CLEMASTINE FUMARATE

CLEMASTINE FUMARATE

Loss of exclusivity—loss of exclusivity
CompanyOMNIVIUM PHARMACEUTICALS LLC

Drug detail

Brand nameCLEMASTINE FUMARATE
Active ingredientCLEMASTINE FUMARATE
Strength2.68MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 1993
Marketing statusDISCN

More from OMNIVIUM PHARMACEUTICALS LLC

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CLEMASTINE FUMARATE patent cliff — loss of exclusivity — | CliffBio